Introduction

In 2025, a global top 20 pharmaceutical sponsor required end-to-end medical writing support for a Phase 1 paediatric asthma study in the US. The sponsor lacked internal expertise to develop a complex Clinical Study Report (CSR), driven by multiple primary, and secondary endpoints, evolving output requirements, and paediatric regulatory considerations. An experienced partner was therefore required to lead development and finalisation.

Objectives and Key Challenges

The sponsor’s objectives were clear:

• Deliver a regulatory-compliant CSR aligned with ICH E3 and paediatric reporting expectations
• Provide submission-ready documentation within 6 months of LSLV (Last Subject Last Visit)

The main challenge was managing a high level of complexity driven by multiple endpoints, evolving TLF structures, and the need to ensure complete alignment between statistical outputs and narrative interpretation, all under a compressed timeline.

The task was therefore not only to draft high-quality content, but also to maintain consistency across the report as the presentation of results evolved. This introduced a risk of inconsistencies between statistical outputs and narrative interpretations, which could delay finalisation if not managed proactively.

Strategic Approach and Tailored Solutions

QInscribe adopted a structured, senior-led approach combining clear ownership, disciplined review processes, and proactive sponsor engagement to ensure timely decision-making and consistent implementation across the document.

This model, supported by independent scientific review and QC ensured robust oversight, enabling early identification of inconsistencies and reducing downstream rework during sponsor review cycles.

When the sponsor requested changes to results presentation for some endpoints, QInscribe managed the update in a controlled, document-wide manner. A structured approach was applied to maintain alignment between evolving TLFs and CSR narrative, ensuring consistency and preventing downstream reconciliation challenges.

Global team coverage across EST and IST enabled near-continuous progress, reducing turnaround times for revisions and minimising timeline risk.

Successful Client Outcomes and Conclusion

The CSR was delivered in alignment with submission timelines (within 6 months of LSLV), with minimal iterative revisions required during final review cycles, reflecting strong upstream alignment and quality control. The sponsor specifically recognised the consistency of narrative interpretation and the ability to adapt efficiently to evolving output requirements.

This case study demonstrates QInscribe’s ability to deliver complex, submission-ready CSRs in high-pressure environments by combining therapeutic expertise, disciplined execution, and the agility to respond effectively to evolving sponsor requirements.